|
Following the completion of the mandatory public tender offer, Novartis (www.novartis.com) announced on September 25, 2008 that it holds 99.8% of the current outstanding public shares in Speedel Holding Ltd. The “squeeze-out” procedure for the remaining shareholders is underway. Operations are being transferred to Novartis, with a completion date anticipated by the end 2008. Legal processes are foreseen to be concluded in early 2009. If you have any questions around the acquisition and integration
of Speedel into Novartis as well as the appropriate business contact
within Novartis please refer to:
|
